Chronic Kidney Disease

Chronic Kidney Disease Staging and Management

Key Points

• Chronic kidney disease (CKD) is progressive loss of kidney function with impaired fluid and waste regulation.
• CKD staging is based on glomerular filtration rate (GFR), from Stage 1 at 90 or higher to Stage 5 below 15 mL/min/1.73 m2.
• Typical CKD laboratory trends include increased creatinine and BUN, decreased GFR, elevated potassium and phosphorus, and decreased calcium.
• Advanced disease may require dialysis or kidney transplantation to maintain life and metabolic stability.
• Renal nutrition plans commonly limit sodium, potassium, phosphorus, and sometimes protein to reduce toxin/mineral accumulation and symptom burden.
• In advanced CKD, protein targets are dialysis-dependent: commonly lower before dialysis and higher once dialysis begins.
• In many nondialysis CKD plans, limits are often near protein 0.6-0.8 g/kg/day, phosphorus 800-1,000 mg/day, and potassium below about 2,000 mg/day with lab-based adjustment.
• Nursing priorities focus on fluid and electrolyte balance, blood pressure control, medication safety, and self-management support.

Pathophysiology

CKD is a gradual, long-term decline in renal function that reduces filtration, fluid regulation, and endocrine roles of the kidneys. CKD is defined as kidney dysfunction that persists longer than three months. As function worsens, waste products and excess fluid accumulate, and dysregulation of electrolyte and hormone systems creates multisystem complications.

Early CKD is often insidious with few obvious symptoms, which increases risk of delayed diagnosis until functional decline is more advanced.

Disease progression is influenced by reduced renal perfusion and direct kidney injury from conditions such as diabetes, hypertension, heart disease, obesity, smoking/tobacco exposure, atherosclerosis, glomerular disorders, pyelonephritis and other recurrent urinary tract infection patterns, kidney stones, prolonged urinary obstruction (for example enlarged prostate or urinary tumors), polycystic kidney disease, autoimmune disease, and chronic nephrotoxic medication exposure (for example NSAIDs and selected antibiotics).

Risk burden is higher in older adults (especially over 40), those with family history of CKD, clients with abnormal kidney structure, and populations with elevated CKD prevalence, including African American, Hispanic, Native American, and Asian American groups.

Classification

• Stage 1: Normal GFR, 90 or higher mL/min/1.73 m2.
• Stage 2: Mild reduction in GFR, 60-89 mL/min/1.73 m2.
• Stage 3: Moderate reduction in GFR, 30-59 mL/min/1.73 m2.
• Stage 4: Severe reduction in GFR, 15-29 mL/min/1.73 m2.
• Stage 5: Kidney failure (end-stage), below 15 mL/min/1.73 m2.

Nursing Assessment

NCLEX Focus

Prioritize trend recognition for renal decline, fluid overload, and high-risk electrolyte abnormalities.

• Assess for progressive symptoms such as weakness/fatigue, dyspnea, generalized edema (including puffiness around the eyes), appetite decline, concentration difficulty, urination-pattern changes, pruritus, and metallic taste.
• Recognize that early-stage CKD can be asymptomatic and requires trend-based surveillance despite limited symptom burden.
• Watch for frequent urge to void with increasingly small urine amounts as a potential worsening renal-failure cue.
• Monitor for progression cues commonly seen in advanced decline, including resistant hypertension, chest pain, sleep disturbance, nausea/vomiting, and worsening cognitive changes.
• Monitor blood pressure, intake/output, daily weight trends, and signs of fluid overload or dehydration.
• Trend kidney function and electrolyte labs, including creatinine, BUN, GFR, potassium, phosphorus, calcium, and CBC for anemia.
• Assess cardiovascular complications, including edema-related hypertension, dysrhythmia risk with hyperkalemia, heart-murmur changes from overload states, and advanced-stage pericarditis cues.
• Assess multisystem complications, including cognitive change from uremia, GI bleeding risk from platelet dysfunction, and musculoskeletal decline such as muscle cramping or renal osteodystrophy-related bone pain/fracture risk.
• Review urinalysis patterns (protein, blood, infection cues) and diagnostic-imaging plans (ultrasound, CT, or biopsy) when evaluating structural causes, obstruction, or tumor.
• Review dialysis access status and signs of access complications when renal replacement therapy is in use.
• Assess CKD risk-profile domains explicitly (diabetes, hypertension, obesity, tobacco use, family history, and congenital/structural kidney abnormalities) to prioritize prevention teaching and surveillance cadence.
• Assess adherence barriers that make renal nutrition plans unrealistic (food insecurity, heavy reliance on processed foods, and severe thirst burden during fluid restriction).

Nursing Interventions

• Implement stage-appropriate fluid and electrolyte management with prescribed restrictions and frequent reassessment.
• Administer and monitor medications for blood pressure control, anemia support, and electrolyte correction.
• For CKD-associated low erythropoietin states, support ordered erythropoiesis-stimulating therapy and trend hemoglobin response with renal-team guidance.
• Reinforce renal nutrition strategy with sodium, potassium, phosphorus, protein, and fluid guidance (for sodium, often about 1,500-2,300 mg/day depending on plan).
• Reinforce practical renal-portion anchors when ordered (for example many plans limit protein servings to about 2-3 oz per meal and use stage-based fluid targets, often around 2,000 mL/day before tighter advanced-stage limits).
• In Stage 4-5 CKD, reinforce that protein targets often shift by dialysis status (lower before dialysis, then higher after dialysis starts) using nephrology/dietitian guidance.
• Coordinate early dietitian referral for individualized CKD meal planning to delay progression, reduce complications, and improve quality of life.
• Coordinate dialysis care and reinforce adherence to treatment schedules and pre/post treatment monitoring.
• Coordinate dialysis care to support maintenance of individualized dry-weight targets and reduce recurrent overload symptoms.
• During prescribed fluid restriction, provide dry-mouth comfort strategies such as hard candy, ice chips, or breath spray when allowed by plan/policy.
• For dialysis-dependent clients, reinforce strict daily fluid limits when ordered (often near 32 oz/day) and include hidden-fluid sources such as gelatin, ice cream, soup, and ice.
• Teach label checks for phosphorus additives (for example “phosphate,” “phosphoric,” or “pyrophosphate”) and coach reduction of fast/processed foods that concentrate sodium and phosphorus.
• Reinforce use of herbs/spices instead of potassium-based salt substitutes when potassium restriction is ordered.
• Screen for food-security barriers and connect clients to appropriate nutrition-assistance resources early in the plan.
• Reinforce smoking-cessation support and diabetes glucose-control adherence to reduce ongoing renal injury risk.
• Prioritize early treatment of upstream metabolic and vascular conditions (for example diabetes and hypertension) to slow CKD progression and reduce dialysis risk.
• Support transplant-readiness pathways for eligible end-stage clients and reinforce lifelong immunosuppressant adherence after transplantation.
• Provide health teaching on nephrotoxic medication avoidance, daily weight surveillance (including dialysis-day weights), early symptom reporting, and psychosocial coping resources such as support groups.

End-Stage Decompensation Risk

Late-stage CKD can rapidly destabilize through fluid overload, severe electrolyte disturbance, dysrhythmia, and uremic complications.

Pharmacology

Drug Class	Examples	Key Nursing Considerations
ace-inhibitors	class-based agents	Support blood pressure and kidney protection; monitor tolerance.
angiotensin-ii-receptor-blockers	class-based agents	Alternative blood pressure and renal-protection pathway.
hematopoietic-growth-factors	class-based agents	Address CKD-related anemia; trend hemoglobin response.
phosphate-binders	class-based agents	Reduce phosphorus absorption to support mineral balance.
potassium-balance-disorders (potassium-lowering-agents)	sodium polystyrene	Used for hyperkalemia risk reduction with ongoing lab reassessment.
calcium-balance-disorders (calcium-supplements)	class-based agents	Support calcium replacement when CKD-related hypocalcemia is present.

Clinical Judgment Application

Clinical Scenario

A client with Stage 4 CKD presents with worsening edema, rising blood pressure, dyspnea on exertion, and lab trends showing falling GFR with elevated potassium and phosphorus.

• Recognize Cues: Fluid overload signs plus worsening renal and electrolyte trends.
• Analyze Cues: Progressive renal decline is increasing cardiopulmonary and dysrhythmia risk.
• Prioritize Hypotheses: Highest priority is preventing life-threatening decompensation from fluid and potassium imbalance.
• Generate Solutions: Intensify monitoring, optimize medications, and reinforce fluid/electrolyte restrictions.
• Take Action: Implement provider orders, monitor closely, and escalate deterioration promptly.
• Evaluate Outcomes: Edema and blood pressure improve, and critical electrolyte values stabilize.

Related Concepts

• diabetes-mellitus - Major upstream contributor to CKD progression and vascular injury.
• hypertension-assessment-and-management - Shared blood pressure-control priority to reduce renal decline.
• peritoneal-and-hemodialysis-nursing-management - Renal replacement pathway for Stage 5 kidney failure.
• fluid-volume-overload-hypervolemia - Common CKD consequence requiring active surveillance.
• potassium-balance-disorders - Hyperkalemia risk in CKD with potential dysrhythmia complications.

Self-Check

1. Which GFR ranges define CKD Stages 3, 4, and 5?
2. Which laboratory pattern most strongly suggests progressive CKD with mineral imbalance?
3. Why are fluid, electrolyte, and blood pressure trends central to CKD safety monitoring?